Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
复制标题
DOI：
10.1016/j.vaccine.2012.02.001
复制
发表时间：
2012-03-30
期刊：
影响因子：
5.5
通讯作者：
Heyward, William L.
中科院分区：
文献类型：
--
作者：
Sablan, Benjamin P.;Kim, Dong Joon;Heyward, William L.
40岁及以上的成年人已被证明对目前可用的B型肝炎病毒（HBV）疫苗免疫应答低下。Toll样受体9激动剂、1018免疫刺激序列（1018 ISS）佐剂与重组乙型肝炎B表面抗原（HBsAg）联合肌肉注射3次，证明了比3次已获许可的对照HBV疫苗（Engerix-B（R））更快、更上级、更持久的血清保护作用。该试验用疫苗HBsAg-1018 ISS耐受性良好，安全性特征与对照疫苗相似。这些结果表明，HBsAg-1018可能在该低应答人群中更有效。(C)2012爱思唯尔有限公司保留所有权利。
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B (R)). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population. (C) 2012 Elsevier Ltd. All rights reserved.